Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 218

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 218
---
13,501 Investing activities    Purchases of marketable securities(251,655)(491,047)Proceeds from maturities and redemption of marketable securities387,297 452,520 Purchases of property and equipment, net(6,617)(2,874)Net cash provided by (used in) investing activities129,025 (41,401)Financing activities    Proceeds from issuance of Convertible Notes (Note 7)39,708 - Payment for debt issuance costs (Note 7)(4,500)- Payments for debt extinguishment (Note 7)(80,938)- Proceeds from unwind of capped call options (Note 7)46,554 - Payments for repurchase of common stock (Note 11)(101,207)- Proceeds from exercise of stock options6,833 3,925 Proceeds from Employee Stock Purchase Plan1,499 1,760 Payments for taxes related to net share settlement of restricted and performance stock units(11,810)(8,827)Net cash used in financing activities(103,861)(3,142)Effect of exchange rate changes on cash and cash equivalents, and restricted cash1,613 98 Net increase (decrease) in cash and cash equivalents, and restricted cash64,398 (30,944)Cash and cash equivalents, and restricted cash at beginning of period96,154 150,556 Cash and cash equivalents, and restricted cash at end of period$160,552 $119,612 Supplemental disclosure of cash flow information    Cash paid during the period for income taxes$2,605 $4,577 Cash paid during the period for interest$2,021 $2,819 Non-cash investing and financing activities:    Purchases of property and equipment, not yet paid$2,105 $762 Right-of-use assets obtained in exchange of operating lease liabilities$405 $- See accompanying notes.

8

Dynavax Technologies Corporation 

Notes to Condensed Consolidated Financial Statements 

(Unaudited) 

1. Organization

Dynavax Technologies Corporation (“we,” “our,” “us,” “Dynavax” or the “Company”) is a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Our first marketed product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant),